Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Discovery Study to Identify Patients With Advanced Urothelial Cancer Benefitting From Pembrolizumab Treatment

NCT03263039 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT03263039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03263039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Discovery Study to Identify Patients With Advanced Urothelial Cancer Benefitting From Pembrolizumab Treatment
Lead sponsor
Erasmus Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
August 21, 2017
Completion date
August 19, 2023
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarkers, transitional cell carcinoma of the bladder